Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Remon

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Cancer Treatment Reviews|November 19, 2025
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategiesD Miliziano, C Sciortino, S Manglaviti, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 8, 2020
Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical OncologyJ Remon, R García-Campelo, E de Álava, et al.
ESMO Open|September 5, 2025
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?J Remon, F Porez, H Clermidy, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 28, 2019
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical OncologyJ Remon, R García-Campelo, E de Álava, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 10, 2016
Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinomaM Caro, A Font, S Comas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroupsC R Lindsay, V Faugeroux, S Michiels, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsM Charrier, L Mezquita, B Lueza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNAJ Remon, C Caramella, C Jovelet, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 30, 2017
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 databaseJ Remon, D Isla, P Garrido, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Cancer Treatment Reviews|November 19, 2025
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategiesD Miliziano, C Sciortino, S Manglaviti, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 8, 2020
Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical OncologyJ Remon, R García-Campelo, E de Álava, et al.
ESMO Open|September 5, 2025
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?J Remon, F Porez, H Clermidy, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 28, 2019
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical OncologyJ Remon, R García-Campelo, E de Álava, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 10, 2016
Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinomaM Caro, A Font, S Comas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroupsC R Lindsay, V Faugeroux, S Michiels, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patientsM Charrier, L Mezquita, B Lueza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2017
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNAJ Remon, C Caramella, C Jovelet, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 30, 2017
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 databaseJ Remon, D Isla, P Garrido, et al.
Pageof 6